But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.

Western data on EO-3021 fail to live up to the billing of a Chinese trial.

The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?

Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.